Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Zhejiang Shouxiangu Pharmaceutical

SHSE:603896
Snowflake Description

Flawless balance sheet with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
603896
SHSE
CN¥4B
Market Cap
  1. Home
  2. CN
  3. Household
Company description

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. The last earnings update was 46 days ago. More info.


Add to Portfolio Compare Print
603896 Share Price and Events
7 Day Returns
5.6%
SHSE:603896
-1.5%
CN Personal Products
-0.1%
CN Market
1 Year Returns
-33.6%
SHSE:603896
-16%
CN Personal Products
-9.2%
CN Market
603896 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Zhejiang Shouxiangu Pharmaceutical (603896) 5.6% -6.7% -6.7% -33.6% - -
CN Personal Products -1.5% -5.5% -4.5% -16% -21.6% -44.8%
CN Market -0.1% -9.8% -6.1% -9.2% -16.2% -26.5%
1 Year Return vs Industry and Market
  • 603896 underperformed the Personal Products industry which returned -16% over the past year.
  • 603896 underperformed the Market in China which returned -9.2% over the past year.
Price Volatility
603896
Industry
5yr Volatility vs Market

603896 Value

 Is Zhejiang Shouxiangu Pharmaceutical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Zhejiang Shouxiangu Pharmaceutical to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Zhejiang Shouxiangu Pharmaceutical.

SHSE:603896 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 8.3%
Perpetual Growth Rate 10-Year CN Government Bond Rate 3.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SHSE:603896
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CN Govt Bond Rate 3.2%
Equity Risk Premium S&P Global 6.3%
Personal Products Unlevered Beta Simply Wall St/ S&P Global 0.59
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.594 (1 + (1- 25%) (0.5%))
0.729
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.2% + (0.8 * 6.33%)
8.26%

Discounted Cash Flow Calculation for SHSE:603896 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Zhejiang Shouxiangu Pharmaceutical is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

SHSE:603896 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CNY, Millions) Source Present Value
Discounted (@ 8.26%)
2020 68.54 Est @ 12.61% 63.31
2021 75.25 Est @ 9.78% 64.20
2022 81.12 Est @ 7.81% 63.93
2023 86.34 Est @ 6.43% 62.84
2024 91.05 Est @ 5.46% 61.21
2025 95.40 Est @ 4.78% 59.25
2026 99.51 Est @ 4.31% 57.08
2027 103.47 Est @ 3.97% 54.82
2028 107.34 Est @ 3.74% 52.53
2029 111.18 Est @ 3.58% 50.26
Present value of next 10 years cash flows CN¥589.00
SHSE:603896 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CN¥111.18 × (1 + 3.2%) ÷ (8.26% – 3.2%)
CN¥2,265.75
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CN¥2,265.75 ÷ (1 + 8.26%)10
CN¥1,024.17
SHSE:603896 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CN¥589.00 + CN¥1,024.17
CN¥1,613.17
Equity Value per Share
(CNY)
= Total value / Shares Outstanding
= CN¥1,613.17 / 143.52
CN¥11.24
SHSE:603896 Discount to Share Price
Calculation Result
Value per share (CNY) From above. CN¥11.24
Current discount Discount to share price of CN¥27.96
= -1 x (CN¥27.96 - CN¥11.24) / CN¥11.24
-148.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Zhejiang Shouxiangu Pharmaceutical is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Zhejiang Shouxiangu Pharmaceutical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Zhejiang Shouxiangu Pharmaceutical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SHSE:603896 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in CNY CN¥0.88
SHSE:603896 Share Price ** SHSE (2020-04-03) in CNY CN¥27.96
China Personal Products Industry PE Ratio Median Figure of 13 Publicly-Listed Personal Products Companies 31.77x
China Market PE Ratio Median Figure of 3,196 Publicly-Listed Companies 32.32x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Zhejiang Shouxiangu Pharmaceutical.

SHSE:603896 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SHSE:603896 Share Price ÷ EPS (both in CNY)

= 27.96 ÷ 0.88

31.77x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Zhejiang Shouxiangu Pharmaceutical is good value based on earnings compared to the CN Personal Products industry average.
  • Zhejiang Shouxiangu Pharmaceutical is good value based on earnings compared to the China market.
Price based on expected Growth
Does Zhejiang Shouxiangu Pharmaceutical's expected growth come at a high price?
Raw Data
SHSE:603896 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 31.77x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
China Personal Products Industry PEG Ratio Median Figure of 6 Publicly-Listed Personal Products Companies 2.44x
China Market PEG Ratio Median Figure of 1,275 Publicly-Listed Companies 1.26x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Zhejiang Shouxiangu Pharmaceutical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Zhejiang Shouxiangu Pharmaceutical's assets?
Raw Data
SHSE:603896 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in CNY CN¥7.46
SHSE:603896 Share Price * SHSE (2020-04-03) in CNY CN¥27.96
China Personal Products Industry PB Ratio Median Figure of 15 Publicly-Listed Personal Products Companies 2.59x
China Market PB Ratio Median Figure of 3,691 Publicly-Listed Companies 2.26x
SHSE:603896 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SHSE:603896 Share Price ÷ Book Value per Share (both in CNY)

= 27.96 ÷ 7.46

3.75x

* Primary Listing of Zhejiang Shouxiangu Pharmaceutical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Zhejiang Shouxiangu Pharmaceutical is overvalued based on assets compared to the CN Personal Products industry average.
X
Value checks
We assess Zhejiang Shouxiangu Pharmaceutical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. Zhejiang Shouxiangu Pharmaceutical has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

603896 Future Performance

 How is Zhejiang Shouxiangu Pharmaceutical expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Zhejiang Shouxiangu Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
27.4%
Expected Personal Products industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Zhejiang Shouxiangu Pharmaceutical expected to grow at an attractive rate?
  • Unable to compare Zhejiang Shouxiangu Pharmaceutical's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Zhejiang Shouxiangu Pharmaceutical's earnings growth to the China market average as no estimate data is available.
  • Unable to compare Zhejiang Shouxiangu Pharmaceutical's revenue growth to the China market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
SHSE:603896 Future Growth Rates Data Sources
Data Point Source Value (per year)
China Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 27.4%
China Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 16.6%
China Market Earnings Growth Rate Market Cap Weighted Average 20.9%
China Market Revenue Growth Rate Market Cap Weighted Average 15.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SHSE:603896 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CNY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SHSE:603896 Future Estimates Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
SHSE:603896 Past Financials Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income *
2019-12-31 547 124
2019-09-30 531 191 105
2019-06-30 539 180 100
2019-03-31 550 186 115
2018-12-31 511 172 108
2018-09-30 461 153 98
2018-06-30 430 147 102
2018-03-31 409 131 100
2017-12-31 370 111 89
2017-09-30 342 113 89
2017-06-30 333 100 85
2017-03-31 317 101 84

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Zhejiang Shouxiangu Pharmaceutical is high growth as no earnings estimate data is available.
  • Unable to determine if Zhejiang Shouxiangu Pharmaceutical is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SHSE:603896 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Zhejiang Shouxiangu Pharmaceutical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SHSE:603896 Future Estimates Data
Date (Data in CNY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
SHSE:603896 Past Financials Data
Date (Data in CNY Millions) EPS *
2019-12-31 0.88
2019-09-30 0.74
2019-06-30 0.71
2019-03-31 0.81
2018-12-31 0.76
2018-09-30 0.69
2018-06-30 0.72
2018-03-31 0.75
2017-12-31 0.71
2017-09-30 0.76
2017-06-30 0.79
2017-03-31 0.80

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Zhejiang Shouxiangu Pharmaceutical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Check out Zhejiang Shouxiangu Pharmaceutical's track record over time to understand how much the company has returned to shareholders and its earnings growth rate in the past.
  2. Zhejiang Shouxiangu Pharmaceutical's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Household companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Zhejiang Shouxiangu Pharmaceutical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Zhejiang Shouxiangu Pharmaceutical has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

603896 Past Performance

  How has Zhejiang Shouxiangu Pharmaceutical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Zhejiang Shouxiangu Pharmaceutical's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Zhejiang Shouxiangu Pharmaceutical's year on year earnings growth rate has been positive over the past 5 years.
  • Zhejiang Shouxiangu Pharmaceutical's 1-year earnings growth exceeds its 5-year average (15.3% vs 11.6%)
  • Zhejiang Shouxiangu Pharmaceutical's earnings growth has exceeded the CN Personal Products industry average in the past year (15.3% vs -0.4%).
Earnings and Revenue History
Zhejiang Shouxiangu Pharmaceutical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Zhejiang Shouxiangu Pharmaceutical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SHSE:603896 Past Revenue, Cash Flow and Net Income Data
Date (Data in CNY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 546.76 124.12
2019-09-30 530.80 104.66 319.82 41.01
2019-06-30 538.95 100.39 333.26 38.43
2019-03-31 550.40 114.79 334.56 35.09
2018-12-31 511.45 107.65 309.17 33.67
2018-09-30 460.76 98.08 280.78 31.27
2018-06-30 429.91 101.96 247.49 35.32
2018-03-31 408.99 100.41 232.04 29.55
2017-12-31 369.96 88.88 213.68 20.97
2017-09-30 342.02 88.79 193.43 9.71
2017-06-30 333.07 85.12 199.52
2017-03-31 317.43 83.77 187.31
2016-12-31 314.88 80.98 187.79
2015-12-31 301.91 62.64 177.77
2014-12-31 301.59 69.25 149.09
2013-12-31 253.03 54.05 105.83

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Zhejiang Shouxiangu Pharmaceutical has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Zhejiang Shouxiangu Pharmaceutical used its assets more efficiently than the CN Personal Products industry average last year based on Return on Assets.
  • Zhejiang Shouxiangu Pharmaceutical's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Zhejiang Shouxiangu Pharmaceutical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Zhejiang Shouxiangu Pharmaceutical has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

603896 Health

 How is Zhejiang Shouxiangu Pharmaceutical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Zhejiang Shouxiangu Pharmaceutical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Zhejiang Shouxiangu Pharmaceutical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Zhejiang Shouxiangu Pharmaceutical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Zhejiang Shouxiangu Pharmaceutical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 27.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Zhejiang Shouxiangu Pharmaceutical Company Filings, last reported 3 months ago.

SHSE:603896 Past Debt and Equity Data
Date (Data in CNY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 1,073.50 20.00 344.02
2019-09-30 1,073.50 20.00 344.02
2019-06-30 1,053.28 20.00 335.36
2019-03-31 1,043.90 40.00 232.35
2018-12-31 984.74 40.00 331.52
2018-09-30 922.86 14.90 31.22
2018-06-30 901.10 10.00 295.01
2018-03-31 905.92 10.00 188.61
2017-12-31 869.75 0.00 307.19
2017-09-30 831.66 0.00 66.58
2017-06-30 820.12 0.00 279.95
2017-03-31 444.80 115.60 16.35
2016-12-31 436.93 123.00 15.34
2015-12-31 368.53 167.60 33.74
2014-12-31 320.56 104.00 40.90
2013-12-31 299.50 54.50 77.13
  • Zhejiang Shouxiangu Pharmaceutical's level of debt (1.9%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (32.5% vs 1.9% today).
  • Debt is well covered by operating cash flow (955.9%, greater than 20% of total debt).
  • Zhejiang Shouxiangu Pharmaceutical earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Zhejiang Shouxiangu Pharmaceutical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Zhejiang Shouxiangu Pharmaceutical has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

603896 Dividends

 What is Zhejiang Shouxiangu Pharmaceutical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.82%
Current annual income from Zhejiang Shouxiangu Pharmaceutical dividends.
If you bought CN¥2,000 of Zhejiang Shouxiangu Pharmaceutical shares you are expected to receive CN¥16 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Zhejiang Shouxiangu Pharmaceutical's pays a higher dividend yield than the bottom 25% of dividend payers in China (0.46%).
  • Zhejiang Shouxiangu Pharmaceutical's dividend is below the markets top 25% of dividend payers in China (2.04%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SHSE:603896 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
China Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.7%
China Market Average Dividend Yield Market Cap Weighted Average of 2585 Stocks 1.9%
China Minimum Threshold Dividend Yield 10th Percentile 0.2%
China Bottom 25% Dividend Yield 25th Percentile 0.5%
China Top 25% Dividend Yield 75th Percentile 2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SHSE:603896 Future Dividends Estimate Data
Date (Data in CN¥) Dividend per Share (annual) Avg. No. Analysts
SHSE:603896 Past Annualized Dividends Data
Date (Data in CN¥) Dividend per share (annual) Avg. Yield (%)
2019-06-11 0.230 0.737
2018-07-05 0.200 0.588

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Zhejiang Shouxiangu Pharmaceutical has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Zhejiang Shouxiangu Pharmaceutical only paid a dividend in the past 2 years.
Current Payout to shareholders
What portion of Zhejiang Shouxiangu Pharmaceutical's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (3.8x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Zhejiang Shouxiangu Pharmaceutical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Zhejiang Shouxiangu Pharmaceutical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Zhejiang Shouxiangu Pharmaceutical has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

603896 Management

 What is the CEO of Zhejiang Shouxiangu Pharmaceutical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Zhejiang Shouxiangu Pharmaceutical has no CEO, or we have no data on them.
Management Team

Jing Xu

TITLE
Deputy General Manger and Director
Board of Directors

Jing Xu

TITLE
Deputy General Manger and Director
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CN¥) Value (CN¥)
X
Management checks
We assess Zhejiang Shouxiangu Pharmaceutical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Zhejiang Shouxiangu Pharmaceutical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

603896 News

Simply Wall St News

603896 Company Info

Description

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. researches, develops, and sells Chinese medicine products. It offers Ganoderma lucidum spore powder, Tiepi Fengdou Ganoderma lucidum extract, Tiepi Fengdou granules, saffron Tiepi Fengdou extract, and other products. The company was founded in 1997 and is based in Jinhua, China.

Details
Name: Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
603896
Exchange: SHSE
Founded: 1997
CN¥4,012,913,816
143,523,384
Website: http://www.sxg1909.com
Address: Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
No. 12, Huanglong 3rd Road,
Wuyi County,
Jinhua,
Zhejiang Province, China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SHSE 603896 Domestic Shares Shanghai Stock Exchange CN CNY 10. May 2017
Number of employees
Current staff
Staff numbers
0
Zhejiang Shouxiangu Pharmaceutical employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/04 18:35
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2018/04/03
Last earnings filing: 2020/02/18
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.